Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | V561F |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR1 V561F lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). V561F has been associated with resistance to FGFR inhibitors in culture (PMID: 34114373), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Oct 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR1 mutant FGFR1 V561F |
Transcript | NM_023110.3 |
gDNA | chr8:g.38416041_38416043delGTGinsTTT |
cDNA | c.1681_1683delGTGinsTTT |
Protein | p.V561F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017013221.2 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
NM_023110.2 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38416041_38416043delGTGinsTTT | c.1681_1683delGTGinsTTT | p.V561F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561F demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373). | 34114373 |
FGFR1 V561F | Advanced Solid Tumor | sensitive | Olverembatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth, Fgfr1 phosphorylation, and downstream pathway activation and induced cell cycle arrest and apoptosis in cells expressing FGFR1 V561F in culture and inhibited tumor growth in cell line xenograft models, with a tumor growth inhibition of 73.4% (PMID: 34114373). | 34114373 |
FGFR1 V561F | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment failed to inhibit cell growth, Fgfr1 phosphorylation, and downstream pathway activation in cells expressing FGFR1 V561F in culture and failed to inhibit tumor growth in a cell line xenograft model with a tumor growth inhibition of 2.4% (PMID: 34114373). | 34114373 |
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Pemazyre (pemigatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373). | 34114373 |
FGFR1 V561F | Advanced Solid Tumor | predicted - resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lytgobi (futibatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373). | 34114373 |